Meet Pradeep, a 69-year-old elderly-onset RA patient,1-4 diagnosed just months after his retirement.
‘I’ve always been worried about my health. Having high blood pressure and high cholesterol,5,6 I’m really conscious about keeping everything under control’.
‘When I retired recently, I expected to be more relaxed. That’s when the shock diagnosis came. RA at the age of 69.3-4 It’s really made me uncertain as to how later life will be’.
Compared with younger RA patients, elderly-onset RA patients are >3× less likely to be treated with biologics.7,*
Note: This is a hypothetical case for representation purpose only.
Elderly patients such as Pradeep benefit from long-term disease control and better drug survival with Enbrel®1,2
Improvements in disease activity and function were sustained up to 4 years in elderly patients with recent-onset RA and up to 6 years with late-stage RA1,†
Risk of discontinuation due to severe adverse drug reactions in elderly patients was lower with Enbrel® compared to both adalimumab and infliximab2,‡
From subset analyses of 4 RCTs and 2 long-term extension studies that evaluated a total of 2402 patients with RA.1,†
Observed ACR Response in Recent-onset RA Patients Treated With Open-label Enbrel®1
Adapted from Bathon MJ, et al. 2006.
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From a prospective observational study of 665 patients diagnosed with early RA (symptomatic for <12 months) who were divided into 2 groups: young-onset (<58 years) and late-onset (≥58 years) and followed for over 5 years. Over 5 years, late-onset RA was associated with less frequent treatment with biologics compared with young-onset RA: 7.4% versus 24.6%, respectively, P<0.001.7
†From subset analyses of 4 randomised controlled clinical studies (n=1353) and 2 long-term extension studies (n=1049) of Enbrel®.1
Study design: Bathon MJ, et al. 2006.
Study objectives included the assessments of: whether the efficacy and safety of Enbrel® are similar in elderly (≥65 years) and younger (<65 years) subjects; whether Enbrel® treatment is effective in both elderly and younger subjects who have recent-onset (early) RA or DMARD-refractory (late-stage) RA.1
For the extension studies, ACR responses were presented as ‘observed cases’. Time points were measured from baseline of the extension and did not include study drug exposure in the initial studies. All subjects in the extensions received Enbrel® 25 mg BIW.1
The ERA study (ERA, 016.0012), which compared Enbrel® and MTX therapy, was the sole study through which subjects entered the recent-onset RA extension. Efficacy assessments were measured relative to the baseline of the ERA study.1
‡From a 14-year retrospective longitudinal analysis of 146 patients with RA followed in an outpatient clinic starting bDMARDs after the age of 65 years.2
ACR, American College of Rheumatology; AS, ankylosing spondylitis; bDMARD, biologic disease-modifying antirheumatic drug; BIW, twice a week; DMARD, disease-modifying anti-rheumatic drug; ERA, Early Rheumatoid Arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SmPC, summary of product characteristics.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
Observed ACR Response in Recent-onset RA Patients Treated With Open-label Enbrel®2
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.